CellSeed Inc
TSE:7776
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CellSeed Inc
Additional Paid In Capital
CellSeed Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CellSeed Inc
TSE:7776
|
Additional Paid In Capital
¥104m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
3%
|
|
|
SanBio Co Ltd
TSE:4592
|
Additional Paid In Capital
¥4.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
GNI Group Ltd
TSE:2160
|
Additional Paid In Capital
¥15.8B
|
CAGR 3-Years
36%
|
CAGR 5-Years
34%
|
CAGR 10-Years
11%
|
|
|
PeptiDream Inc
TSE:4587
|
Additional Paid In Capital
¥4.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Takara Bio Inc
TSE:4974
|
Additional Paid In Capital
¥32.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Additional Paid In Capital
¥1.7B
|
CAGR 3-Years
42%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-10%
|
|
CellSeed Inc
Glance View
CellSeed Inc. develops regenerative medicine products. The company is headquartered in Koto-Ku, Tokyo-To and currently employs 44 full-time employees. The company went IPO on 2010-03-16. The firm operates in two business segments. The Regenerative Medical Support segment is engaged in the research, development, manufacture and sale of temperature-responsive cell incubators. The Cell Sheet Regeneration Medical segment is involved in the research and development of cell sheet regenerative medical products.
See Also
What is CellSeed Inc's Additional Paid In Capital?
Additional Paid In Capital
104m
JPY
Based on the financial report for Dec 31, 2025, CellSeed Inc's Additional Paid In Capital amounts to 104m JPY.
What is CellSeed Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
3%
Over the last year, the Additional Paid In Capital growth was -94%. The average annual Additional Paid In Capital growth rates for CellSeed Inc have been -38% over the past three years , -42% over the past five years , and 3% over the past ten years .
